UroGen Pharma (URGN) Profit After Tax Growth (1y) (2018 - 2026)
Powered by 
Analysis
UroGen Pharma (URGN) Profit After Tax Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -8.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 94.83% |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn | 71.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 71.25% |
| Mar 31, 2026 | 46.26% |
| Dec 31, 2025 | 29.71% |
| Sep 30, 2025 | -40.87% |
| Jun 30, 2025 | -49.53% |
| Mar 31, 2025 | -35.72% |
| Dec 31, 2024 | -44.19% |
| Sep 30, 2024 | -8.20% |
| Jun 30, 2024 | -38.39% |
| Mar 31, 2024 | -7.02% |
| Dec 31, 2023 | 9.73% |
| Sep 30, 2023 | 15.62% |
| Jun 30, 2023 | 9.57% |
| Mar 31, 2023 | -6.25% |
| Dec 31, 2022 | -1.19% |
| Sep 30, 2022 | 14.29% |
| Jun 30, 2022 | -1.41% |
| Mar 31, 2022 | -9.10% |
| Dec 31, 2021 | 6.71% |
| Sep 30, 2021 | -4.02% |